EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis

Joel M Dulhunty, Stephen J Brett, Jan J De Waele, Dorrilyn Rajbhandari, Laurent Billot, Menino O Cotta, Joshua S Davis, Simon Finfer, Naomi E Hammond, Serena Knowles, Xiaoqiu Liu, Shay McGuinness und 12 weitere

JAMA · 27.08.2024 · 332 (8) · 629

DOI: 10.1001/jama.2024.9779 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA, erschienen am 27.08.2024. Verfasst von Joel M Dulhunty und 23 weiteren Autor:innen. Beteiligte Einrichtung: Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Intensive Care Units, Meropenem, Piperacillin, Tazobactam Drug Combination, Sepsis. Die Arbeit wurde bisher 184-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Whether β-lactam antibiotics administered by continuous compared with intermittent infusion reduces the risk of death in patients with sepsis is uncertain.

Objective

To evaluate whether continuous vs intermittent infusion of a β-lactam antibiotic (piperacillin-tazobactam or meropenem) results in decreased all-cause mortality at 90 days in critically ill patients with sepsis. Design, Setting, and Participants An international, open-label, randomized clinical trial conducted in 104 intensive care units (ICUs) in Australia, Belgium, France, Malaysia, New Zealand, Sweden, and the United Kingdom. Recruitment occurred from March 26, 2018, to January 11, 2023, with follow-up completed on April 12, 2023. Participants were critically ill adults (≥18 years) treated with piperacillin-tazobactam or meropenem for sepsis.

Intervention

Eligible patients were randomized to receive an equivalent 24-hour dose of a β-lactam antibiotic by either continuous (n = 3498) or intermittent (n = 3533) infusion for a clinician-determined duration of treatment or until ICU discharge, whichever occurred first. Main Outcomes and Measures The primary outcome was all-cause mortality within 90 days after randomization. Secondary outcomes were clinical cure up to 14 days after randomization; new acquisition, colonization, or infection with a multiresistant organism or Clostridioides difficile infection up to 14 days after randomization; ICU mortality; and in-hospital mortality.

Results

Among 7202 randomized participants, 7031 (mean [SD] age, 59 [16] years; 2423 women [35%]) met consent requirements for inclusion in the primary analysis (97.6%). Within 90 days, 864 of 3474 patients (24.9%) assigned to receive continuous infusion had died compared with 939 of 3507 (26.8%) assigned intermittent infusion (absolute difference, −1.9% [95% CI, −4.9% to 1.1%]; odds ratio, 0.91 [95% CI, 0.81 to 1.01]; P = .08). Clinical cure was higher in the continuous vs intermittent infusion group (1930/3467 [55.7%] and 1744/3491 [50.0%], respectively; absolute difference, 5.7% [95% CI, 2.4% to 9.1%]). Other secondary outcomes were not statistically different. Conclusions and Relevance The observed difference in 90-day mortality between continuous vs intermittent infusions of β-lactam antibiotics did not meet statistical significance in the primary analysis. However, the confidence interval around the effect estimate includes the possibility of both no important effect and a clinically important benefit in the use of continuous infusions in this group of patients. Trial Registration ClinicalTrials.gov Identifier: NCT03213990

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intensive Care UnitsMeropenemPiperacillin, Tazobactam Drug CombinationSepsisbeta Lactam AntibioticsAgedFemaleHumansMaleMiddle AgedCritical IllnessDrug Administration ScheduleInfusions, IntravenousAdultHospital Mortality

Substanzen

MeropenemPiperacillin, Tazobactam Drug Combinationbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Redcliffe Hospital, Brisbane, Queensland, Australia.
  • The University of Queensland, Brisbane, Queensland, Australia.
  • Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium.

Zitieren

APA

Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., Liu, X., McGuinness, S., Mysore, J., Paterson, D. L., Peake, S., Rhodes, A., Roberts, J. A., Roger, C., Shirwadkar, C., …, & BLING III Study Investigators (2024). Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis. JAMA, 332(8), 629. https://doi.org/10.1001/jama.2024.9779

Vancouver

Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis. JAMA. 2024;332(8):629. doi:10.1001/jama.2024.9779

BibTeX
@article{Dulhunty2024,
  author = {Dulhunty, Joel M and Brett, Stephen J and De Waele, Jan J and Rajbhandari, Dorrilyn and Billot, Laurent and Cotta, Menino O and Davis, Joshua S and Finfer, Simon and Hammond, Naomi E and Knowles, Serena and Liu, Xiaoqiu and McGuinness, Shay and Mysore, Jayanthi and Paterson, David L and Peake, Sandra and Rhodes, Andrew and Roberts, Jason A and Roger, Claire and Shirwadkar, Charudatt and Starr, Therese and Taylor, Colman and Myburgh, John A and Lipman, Jeffrey and BLING III Study Investigators, BLING III Study Investigators},
  title = {Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {8},
  pages = {629},
  doi = {10.1001/jama.2024.9779}
}
Kostenlos starten →